Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands
Background: Coinciding with the relatively good and improving prognosis for patients with stage I-III breast cancer, late recurrences, new primary tumours and late side-effects of treatment may occur. We gained insight into prognosis for long-term breast cancer survivors. Patients and methods: Data on all 205 827 females aged 15-89 diagnosed with stage I-III breast cancer during 1989-2008 were derived from the Netherlands Cancer Registry. Conditional 5-year relative survival was calculated for every subsequent year from diagnosis up to 15 years. Results: For stage I, conditional 5-year relativ... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2014 |
Reihe/Periodikum: | Janssen-Heijnen , M L G , van Steenbergen , L N , Voogd , A C , Tjan-Heijnen , V C G , Nijhuis , P H , Poortmans , P M , Coebergh , J W W & van Spronsen , D J 2014 , ' Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands ' , Annals of Oncology , vol. 25 , no. 1 , pp. 64-68 . https://doi.org/10.1093/annonc/mdt424 |
Schlagwörter: | conditional survival / breast cancer / long-term survivors / excess mortality / late side-effects / UP-TO-DATE / LIFE EXPECTANCY / PROGNOSIS / DIAGNOSIS / TIME / CHEMOTHERAPY / TRASTUZUMAB / REGISTRIES / THERAPY |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27205760 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://cris.maastrichtuniversity.nl/en/publications/12137c46-520d-4799-b27c-eb3f2e433194 |
Background: Coinciding with the relatively good and improving prognosis for patients with stage I-III breast cancer, late recurrences, new primary tumours and late side-effects of treatment may occur. We gained insight into prognosis for long-term breast cancer survivors. Patients and methods: Data on all 205 827 females aged 15-89 diagnosed with stage I-III breast cancer during 1989-2008 were derived from the Netherlands Cancer Registry. Conditional 5-year relative survival was calculated for every subsequent year from diagnosis up to 15 years. Results: For stage I, conditional 5-year relative survival remained similar to 95% up to 15 years after diagnosis (a stable 5-year excess mortality rate of 5%). For stage II, excess mortality remained 10% for those aged 15-44 or 45-59 and 15% for those aged 60-74. For stage III, excess mortality decreased from 35% at diagnosis to 10% at 15 years for those aged 15-44 or 45-59, and from similar to 40% to 30% for those aged >= 60. Conclusions: Patients with stage I or II breast cancer had a (very) good long-term prognosis, albeit exhibiting a small but significant excess mortality at least up to 15 years after diagnosis. Improvements albeit from a lower level were mainly seen for patients who had been diagnosed with stage III disease. Caregivers can use this information to better inform (especially disease-free) cancer survivors about their actual prognosis.